Endocrine Therapy Plus Targeted Agents in MBC at HealthBulance.

Health care is our expertise. Medscape recently interviewed Erica L. Mayer, MD, MPH, director of clinical research in the Breast Oncology Center at the Dana-Farber Cancer Institute, an institute physician at Dana-Farber, and an associate professor of medicine at Harvard Medical School, Boston,

Medscape

Endocrine Therapy Plus Targeted Agents in MBC

Endocrine Therapy Plus Targeted Agents in MBC

Medscape recently interviewed Erica L. Mayer, MD, MPH, director of clinical research in the Breast Oncology Center at the Dana-Farber Cancer Institute, an institute physician at Dana-Farber, and an associate professor of medicine at Harvard Medical School, Boston, Massachusetts, to gain her insight on adding targeted agents to endocrine therapy (ET) for hormone receptor–positive, human epidermal growth factor 2–negative (HR+/HER2-) metastatic breast cancer (MBC).